New hope for aggressive breast cancer: Three-Drug combo trial launches

NCT ID NCT06690840

Summary

This study is testing whether combining three drugs—atezolizumab, vinorelbine, and cyclophosphamide—can help control advanced triple-negative breast cancer in patients who have already received immunotherapy. The trial aims to see if this combination can shrink tumors and extend survival for people with this aggressive cancer type. Researchers will enroll 45 participants with metastatic disease that cannot be surgically removed.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Sanitaria Locale Br

    NOT_YET_RECRUITING

    Brindisi, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • European Institute of Oncology

    RECRUITING

    Milan, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fondazione IRCCS San Gerardo Dei Tintori

    RECRUITING

    Monza, Monza, 20900, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    NOT_YET_RECRUITING

    Roma, Roma, 00168, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    NOT_YET_RECRUITING

    Roma, Roma, 00168, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.